将不同性别人群纳入 3,4-亚甲二氧基甲基苯丙胺辅助心理治疗试验研究。

IF 3.9 2区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

LGBT health Pub Date : 2024-08-27 DOI:10.1089/lgbt.2024.0103

Ziad Saade, Brady D Hanshaw, Alex S Keuroghlian

{"title":"将不同性别人群纳入 3,4-亚甲二氧基甲基苯丙胺辅助心理治疗试验研究。","authors":"Ziad Saade, Brady D Hanshaw, Alex S Keuroghlian","doi":"10.1089/lgbt.2024.0103","DOIUrl":null,"url":null,"abstract":"Sexually and gender diverse (SGD) populations experience an increased prevalence and severity of posttraumatic stress disorder (PTSD) compared with the general population. Minority stress theory contextualizes this increased disease burden by outlining how stigma and discrimination (e.g., homophobia and transphobia) contribute to worse mental health outcomes. The standard-of-care pharmacotherapy for PTSD is associated with significant treatment resistance. 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) has emerged as an investigational treatment for PTSD but has lacked consideration for SGD populations. This article explores next steps in clinical trial design and implementation for the study of MDMA-AP with SGD populations who have PTSD.","PeriodicalId":18062,"journal":{"name":"LGBT health","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Including Sexually and Gender Diverse Populations in 3,4-Methylenedioxymethamphetamine-Assisted Psychotherapy Trial Research.\",\"authors\":\"Ziad Saade, Brady D Hanshaw, Alex S Keuroghlian\",\"doi\":\"10.1089/lgbt.2024.0103\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sexually and gender diverse (SGD) populations experience an increased prevalence and severity of posttraumatic stress disorder (PTSD) compared with the general population. Minority stress theory contextualizes this increased disease burden by outlining how stigma and discrimination (e.g., homophobia and transphobia) contribute to worse mental health outcomes. The standard-of-care pharmacotherapy for PTSD is associated with significant treatment resistance. 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) has emerged as an investigational treatment for PTSD but has lacked consideration for SGD populations. This article explores next steps in clinical trial design and implementation for the study of MDMA-AP with SGD populations who have PTSD.\",\"PeriodicalId\":18062,\"journal\":{\"name\":\"LGBT health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"LGBT health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/lgbt.2024.0103\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"LGBT health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/lgbt.2024.0103","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

摘要

与普通人群相比，性与性别多元化（SGD）人群创伤后应激障碍（PTSD）的发病率和严重程度都有所增加。少数群体压力理论概述了污名化和歧视（如仇视同性恋和变性者）是如何导致心理健康状况恶化的，从而使疾病负担加重。创伤后应激障碍的标准药物疗法与严重的耐药性有关。3,4-亚甲二氧基甲基苯丙胺（MDMA）辅助心理疗法（MDMA-AP）已成为创伤后应激障碍的一种研究性治疗方法，但尚未考虑用于 SGD 群体。本文探讨了在患有创伤后应激障碍的 SGD 群体中研究 MDMA-AP 的临床试验设计和实施的下一步工作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Including Sexually and Gender Diverse Populations in 3,4-Methylenedioxymethamphetamine-Assisted Psychotherapy Trial Research.

Sexually and gender diverse (SGD) populations experience an increased prevalence and severity of posttraumatic stress disorder (PTSD) compared with the general population. Minority stress theory contextualizes this increased disease burden by outlining how stigma and discrimination (e.g., homophobia and transphobia) contribute to worse mental health outcomes. The standard-of-care pharmacotherapy for PTSD is associated with significant treatment resistance. 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) has emerged as an investigational treatment for PTSD but has lacked consideration for SGD populations. This article explores next steps in clinical trial design and implementation for the study of MDMA-AP with SGD populations who have PTSD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

LGBT health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -

CiteScore

6.60

自引率

6.20%

发文量

期刊介绍： LGBT Health is the premier peer-reviewed journal dedicated to promoting optimal healthcare for millions of sexual and gender minority persons worldwide by focusing specifically on health while maintaining sufficient breadth to encompass the full range of relevant biopsychosocial and health policy issues. This Journal aims to promote greater awareness of the health concerns particular to each sexual minority population, and to improve availability and delivery of culturally appropriate healthcare services. LGBT Health also encourages further research and increased funding in this critical but currently underserved domain. The Journal provides a much-needed authoritative source and international forum in all areas pertinent to LGBT health and healthcare services. Contributions from all continents are solicited including Asia and Africa which are currently underrepresented in sex research.